IL17A and diabetic kidney disease: Simultaneous blockade of VEGF-B and IL-17A signaling using neutralizing antibodies exhibited a synergistic effect on alleviating renal injury and ameliorating the renal function by decreasing lipid deposition, normalizing the proinflammatory content and preventing the renal fibrosis in the DKD mouse model, suggesting that simultaneous blockade of VEGF-B and IL-17A representing a novel effective therapy for DKD treatment.